YM-348

YM-348
Identifiers
	IUPAC name (2S)-1-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)propan-2-amine;
CAS Number	372163-84-3;
PubChem CID	3045225;
IUPHAR/BPS	230;
ChemSpider	2308001;
CompTox Dashboard (EPA)	DTXSID50190708 ;
Chemical and physical data
Formula	C14H17N3O
Molar mass	243.310 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n3cc2ccc1oc(cc1c2n3C[C@@H](N)C)CC;
	InChI InChI=1S/C14H17N3O/c1-3-11-6-12-13(18-11)5-4-10-7-16-17(14(10)12)8-9(2)15/h4-7,9H,3,8,15H2,1-2H3/t9-/m0/s1; Key:QLOOWOVVZLBYHU-VIFPVBQESA-N;
	(verify)

YM-348 is an indazole derivative drug which acts as a potent and selective 5-HT_2C receptor agonist, with an EC₅₀ of 1nM and 15x selectivity over 5-HT_2A, although it only has moderate selectivity of 3x over the closely related 5-HT_2B receptor.[1][2] It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity.[3][4][5][6]

References

Kimura Y, Hatanaka K, Naitou Y, Maeno K, Shimada I, Koakutsu A, et al. (January 2004). "Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist". European Journal of Pharmacology. 483 (1): 37–43. doi:10.1016/j.ejphar.2003.10.004. PMID 14709324.
Shimada I, Maeno K, Kazuta K, Kubota H, Kimizuka T, Kimura Y, et al. (February 2008). "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry. 16 (4): 1966–82. doi:10.1016/j.bmc.2007.10.100. PMID 18035544.
Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (June 2004). "Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats". Brain Research. 1011 (2): 221–7. doi:10.1016/j.brainres.2004.03.032. PMID 15157808. S2CID 23199460.
Smith BM, Thomsen WJ, Grottick AJ (March 2006). "The potential use of selective 5-HT2C agonists in treating obesity". Expert Opinion on Investigational Drugs. 15 (3): 257–66. doi:10.1517/13543784.15.3.257. PMID 16503763. S2CID 22100586.
Nilsson BM (July 2006). "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents". Journal of Medicinal Chemistry. 49 (14): 4023–34. doi:10.1021/jm058240i. PMID 16821762.
Wacker DA, Miller KJ (July 2008). "Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases". Current Opinion in Drug Discovery & Development. 11 (4): 438–45. PMID 18600561.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kimura Y, Hatanaka K, Naitou Y, Maeno K, Shimada I, Koakutsu A, et al. (January 2004). "Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist". European Journal of Pharmacology. 483 (1): 37–43. doi:10.1016/j.ejphar.2003.10.004. PMID 14709324.

[2] Shimada I, Maeno K, Kazuta K, Kubota H, Kimizuka T, Kimura Y, et al. (February 2008). "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry. 16 (4): 1966–82. doi:10.1016/j.bmc.2007.10.100. PMID 18035544.

[3] Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (June 2004). "Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats". Brain Research. 1011 (2): 221–7. doi:10.1016/j.brainres.2004.03.032. PMID 15157808. S2CID 23199460.

[4] Smith BM, Thomsen WJ, Grottick AJ (March 2006). "The potential use of selective 5-HT2C agonists in treating obesity". Expert Opinion on Investigational Drugs. 15 (3): 257–66. doi:10.1517/13543784.15.3.257. PMID 16503763. S2CID 22100586.

[5] Nilsson BM (July 2006). "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents". Journal of Medicinal Chemistry. 49 (14): 4023–34. doi:10.1021/jm058240i. PMID 16821762.

[6] Wacker DA, Miller KJ (July 2008). "Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases". Current Opinion in Drug Discovery & Development. 11 (4): 438–45. PMID 18600561.

YM-348

See also

References